Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on childhood rhabdomyosarcoma.

H P McDowell1

  • 1RLC NHS Trust Alder Hey, Liverpool, UK Dr H P McDowell, Consultant Paediatric Oncologist, RLC NHS Trust Alder Hey, Eaton Road, Liverpool L12 2AP, UK. Heather.McDowell@RLCH.NWEST.NHS.UK

Archives of Disease in Childhood
|March 26, 2003
PubMed
Summary

Childhood rhabdomyosarcoma survival has greatly improved due to earlier diagnosis and specialized care. Molecular subtypes are now identified, guiding tailored treatments and improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Cell death & disease·2014
Same author

Neuroblastoma: contemporary management.

Archives of disease in childhood. Education and practice edition·2009
Same author

Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.

British journal of cancer·2006
Same author

Emergent embolisation to control severe haematuria in Wilms' tumour.

Pediatric surgery international·2005
Same author

Oscillations in NF-kappaB signaling control the dynamics of gene expression.

Science (New York, N.Y.)·2004
Same author

Secondary parkinsonism: an unusual late complication of craniospinal radiotherapy given to a 16-month child.

Medical and pediatric oncology·2002

Area of Science:

  • Pediatric Oncology
  • Molecular Pathology
  • Clinical Research

Background:

  • Childhood rhabdomyosarcoma (RMS) survival rates have significantly improved over the last decade.
  • Early detection and prompt referral to specialized centers are crucial for accurate diagnosis and better outcomes.
  • Advancements in molecular studies have identified distinct RMS subtypes, including those with poorer prognoses.

Purpose of the Study:

  • To highlight the progress in overall survival for childhood rhabdomyosarcoma.
  • To emphasize the importance of early diagnosis and specialized care.
  • To discuss the impact of molecular subtyping on treatment strategies.

Main Methods:

  • Review of recent advancements in childhood rhabdomyosarcoma diagnosis and treatment.
  • Analysis of molecular studies identifying distinct biological subtypes.
  • Overview of current international clinical trial practices.

Main Results:

  • Dramatic improvement in overall survival for childhood rhabdomyosarcoma over the past 10 years.
  • Identification of specific molecular subgroups associated with poorer prognoses.
  • Enhanced ability to administer more appropriate and targeted treatments based on subtype.

Conclusions:

  • Early diagnosis and specialized care are critical for improving childhood rhabdomyosarcoma outcomes.
  • Molecular subtyping is essential for identifying high-risk groups and personalizing treatment.
  • International clinical trials are fundamental for continued advancements in managing this disease.

Related Experiment Videos